Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Endometrial BCL6 Testing in IVF Outcomes

Fertil Steril; ePub 2017 Nov 7; Almquist, et al

Abnormal BCL6 expression is strongly associated with poor reproductive outcomes in in vitro fertilization (IVF) cycles in women with unexplained infertility (UI), a recent study suggests. The prospective cohort study evaluated women with UI for >1 year who underwent testing for endometrial BCL6, in an LH-timed midluteal phase biopsy and completed an IVF cycle and ET. Clinical pregnancy rate (PR) and live birth rate per transfer was compared for women positive or negative for BCL6 expression. An abnormal BCL6 result was defined by an histologic score (>1.4). Researchers found:

  • Women with normal and abnormal BCL6 and those who conceived or not had similar characteristics.
  • Women with low levels of BCL6 expression had a significantly higher clinical PR compared with women with abnormal (high) BCL6 expression. (relative risk [RR], 0.267, for those with normal BCL6 expression; absolute benefit, 47.7%).
  • Live birth rate was also significantly higher in women low BCL6 expression vs women with abnormal BCL6 expression. (RR, 0.19; absolute benefit, 47.3%).


Almquist LD, Likes CE, Stone B, et al. Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: A cohort study. [Published online ahead of print November 7, 2017]. Fertil Steril. doi:10.1016/j.fertnstert.2017.09.017.